TY - JOUR T1 - Does the purported mortality benefit of beta-blocker therapy in heart failure with a preserved ejection fraction apply to patients without prior myocardial infarction? JF - Heart JO - Heart SP - 1135 LP - 1135 DO - 10.1136/heartjnl-2018-313079 VL - 104 IS - 13 AU - Nilay Kumar Y1 - 2018/07/01 UR - http://heart.bmj.com/content/104/13/1135.1.abstract N2 - To the Editor We read with interest the study by Zheng et al in which the authors conducted a meta-analysis of randomised controlled trials to evaluate the effect of different drug classes in heart failure with a preserved ejection fraction (HFpEF). Primary outcome was all-cause mortality and secondary outcome was cardiovascular mortality among other secondary outcomes. The authors found that beta-blocker therapy led to significant reductions in all-cause … ER -